An animal study showed that DS1 combination therapy has better efficacy than monotherapy because of the synergistic effects of decreasing the dihydropyrimidine dehydrogenase levels in tumor cells.21 Another phase II clinical trial also showed good efficacy of the DS1 regimen after adriamycin treatment in the neoadjuvant therapy of breast cancer.22 This evidence concerns the gene DPYD and breast carcinoma.